Compare AMH & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMH | PRAX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 9.6B |
| IPO Year | N/A | 2020 |
| Metric | AMH | PRAX |
|---|---|---|
| Price | $31.13 | $342.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 15 |
| Target Price | $34.86 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 2.7M | 381.1K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.69 | N/A |
| Revenue Next Year | $2.26 | $6,395.88 |
| P/E Ratio | $26.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.22 | $34.89 |
| 52 Week High | $39.49 | $354.87 |
| Indicator | AMH | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 71.75 | 59.58 |
| Support Level | $30.12 | $282.49 |
| Resistance Level | $32.45 | $354.87 |
| Average True Range (ATR) | 0.55 | 19.10 |
| MACD | 0.29 | 3.67 |
| Stochastic Oscillator | 96.32 | 86.31 |
American Homes 4 Rent is a real estate investment trust focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's geographical markets include Dallas, Texas; Indianapolis, Indiana; Atlanta, Georgia; and Charlotte, North Carolina in terms of the number of properties in each.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.